A CRISPR on-off switch for genes controls expression without altering DNA
A new gene silencing tool allows scientists to switch genes on and off without altering genetic sequences. The tool, described in a paper published in Cell on April 9, uses a modified CRISPR-Cas9 system to introduce reversible epigenetic changes that control gene expression. Read More
Sanofi acquires Tidal Therapeutics, expands vaccine manufacturing
Sanofi announced that it has purchased Tidal Therapeutics for $160 million and plans to expand its vaccine manufacturing capability through a site in Singapore. Read More
Akston begins 2nd-generation COVID-19 vaccine trial
Akston Biosciences has begun a phase I/II clinical trial for its second-generation COVID-19 vaccine. Read More
Avantor to acquire liquid handling manufacturer Ritter for $1B
Avantor has entered into an agreement to acquire liquid handling consumables firm Ritter and its affiliates for approximately $1.05 billion in an all-cash transaction. Read More
Mirum licenses two PFIC gene therapies from Vivet
Mirum Pharmaceuticals has obtained exclusive worldwide rights to develop and commercialize two proprietary adeno-associated virus gene therapy programs from Vivet Therapeutics for progressive familial intrahepatic cholestasis (PFIC). Read More
BioTools Innovator seeks to boost startups developing life science tools
BioTools Innovator is calling for applications to its inaugural competition to advance innovation by accelerating the growth of startups developing life science tools. Kathryn Zavala, PhD, managing director, recently discussed the program with ScienceBoard.net. Read More
NIH recommends outpatient use of Regeneron's COVID-19 antibody cocktail
Regeneron Pharmaceuticals said the U.S. National Institutes of Health (NIH) strongly recommends its Regen-CoV as an outpatient treatment for COVID-19 patients at high risk of clinical progression. Read More
Oncolytic virus shows therapeutic promise against skin cancer
Coxsackievirus combined with immunotherapy appears safe and effective against advanced skin cancer in patients who are unable to have their tumors surgically removed, according to a study to be presented at the American Association for Cancer Research 2021 annual meeting. Read More
Deargen optimizes prediction of candidate drug structures
Artificial intelligence drug discovery and development company Deargen is touting results of its controlled molecular generator technology that overcomes limitations associated with existing models of predicting molecule properties. Read More
NIH details progress of SCGE consortium
The U.S. National Institutes of Health (NIH) Somatic Cell Genome Editing (SCGE) consortium has provided a detailed update, published in Nature on April 8, of projects to develop safer and more effective genome editing methods in somatic cells. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter